Stay updated with breaking news from Axentis pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Search jobs Immunodiagnostics and Vaccine Development at Viravaxx AG Gain Momentum Vienna (Austria), Jan 11, 2021. Fast-track development of vaccines against COVID-19 and other infectious diseases are facilitated by microarray-based assays for whole-proteome analysis and vaccine design platforms. Both have been developed by Viravaxx AG, and the company’s recent progress with its SARS-CoV-2 Interaction Assay offered a turning point.
Concomitantly, as of Jan 1, 2021, Viravaxx has recruited Dr. Helmut Brunar as its new CEO. Dr. Brunar brings vast expertise in vaccines, cell-therapies and diagnostic products to the company. Before joining Viravaxx, he managed supply chain activities at Johnson & Johnson’s COVID-19 vaccine program. Prior to this, he was CEO & Chairman with Axentis Pharma AG where he built a team to develop respiratory drug candidate AX-TOBRA. Dr. Brunar will take over from Dr. Rainer Henning, who has made invaluable co ....